New drug offers hope for rare, severe high-triglyceride conditions
NCT ID NCT06796426
First seen Jan 09, 2026 · Last updated May 22, 2026 · Updated 15 times
Summary
This program provides plozasiran to adults and adolescents with familial chylomicronemia syndrome (FCS) and adults with high-risk severe hypertriglyceridemia (SHTG) whose high triglyceride levels are not controlled by standard treatments. Participants receive injections every 3 months for 15-21 months to lower triglycerides and reduce the risk of pancreatitis. The goal is to manage the condition, not cure it.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FAMILIAL CHYLOMICRONEMIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Arrowhead Pharmaceuticals, Inc.
AVAILABLEPasadena, California, 91105, United States
Conditions
Explore the condition pages connected to this study.